18282-Breast Cancer-NA-294

Breast Cancer

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

  • Details

ClinicalTrials.gov ID: NCT03901339
Diagnosis Type: NA
USOR Number:

  • Address

1760 E. Ken Pratt Blvd. Suite 302
Longmont, CO 80504
P: (303) 684-1900

Search by practice name, trial titles, indicators and specific disease types.